Retrieve available abstracts of 38 articles: HTML format
Single Articles
August 2025
Extending the duration of endocrine treatment for early breast cancer:
patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in
22 031 postmenopausal women already treated with at least 5 years of endocrine
therapy.
Lancet. 2025;406:603-614. PubMedAbstract available
HOWELL SJ, Palmieri C Extending aromatase inhibitor treatment in early breast cancer; longer is better
for many.
Lancet. 2025;406:573-575. PubMed
BRAIN E, Mir O, Bourbouloux E, Rigal O, et al Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for
women aged 70 years and older with high-risk breast cancer based on the genomic
grade index (ASTER 70s): a randomised phase 3 trial.
Lancet. 2025;406:489-500. PubMedAbstract available
LINN SC, Hilbers FS Balancing quality and quantity of life in older patients with breast cancer.
Lancet. 2025;406:422-424. PubMed
May 2025
GILBERT FJ, Payne NR, Allajbeu I, Yit L, et al Comparison of supplemental breast cancer imaging techniques-interim results from
the BRAID randomised controlled trial.
Lancet. 2025 May 21:S0140-6736(25)00582-3. doi: 10.1016/S0140-6736(25)00582. PubMedAbstract available
HOUSSAMI N Breast cancer screening at a crossroads: supplemental imaging for dense breasts.
Lancet. 2025 May 21:S0140-6736(25)00803-7. doi: 10.1016/S0140-6736(25)00803. PubMed
March 2025
PEREZ-GARCIA JM, Gebhart G, Rodriguez-Morato J, Llombart-Cussac A, et al Neoadjuvant therapy in HER2-positive breast cancer and interim PET - Authors'
reply.
Lancet. 2025;405:1055-1056. PubMed
HINDIE E, Groheux D Neoadjuvant therapy in HER2-positive breast cancer and interim PET.
Lancet. 2025;405:1054-1055. PubMed
February 2025
DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al Annual versus less frequent mammographic surveillance in people with breast
cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised,
phase 3, non-inferiority trial.
Lancet. 2025;405:396-407. PubMedAbstract available
MANN RM Rethinking surveillance after breast cancer.
Lancet. 2025;405:356-358. PubMed
October 2024
Reductions in recurrence in women with early breast cancer entering clinical
trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.
Lancet. 2024;404:1407-1418. PubMedAbstract available
TARANTINO P, Tolaney SM Progress in breast cancer management.
Lancet. 2024;404:1376-1378. PubMed
August 2024
MANN GB, Rose AK, Zdenkowski N Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial -
Authors' reply.
Lancet. 2024;404:526. PubMed
KUNKLER I, Cameron D, Dixon M, Williams L, et al Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
Lancet. 2024;404:525. PubMed
SWANICK CW, Kelly P, Dvorak T, Mamounas EP, et al Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
Lancet. 2024;404:525-526. PubMed
MO DC, Huang JF, Luo PH, Wang HL, et al Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
Lancet. 2024;404:524-525. PubMed
July 2024
RUGO HS, Bardia A, Tolaney S Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial -
Authors' reply.
Lancet. 2024;404:339-340. PubMed
HARADA K, Ozaki A, Tanimoto T Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024;404:339. PubMed
MESSORI A Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024;404:338-339. PubMed
GU Y Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024;404:338. PubMed
ERGUN Y Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
Lancet. 2024;404:337-338. PubMed
June 2024
DELALOGE S, Khan SA, Wesseling J, Whelan T, et al Ductal carcinoma in situ of the breast: finding the balance between overtreatment
and undertreatment.
Lancet. 2024;403:2734-2746. PubMedAbstract available
May 2024
PRASAD A Miriam Mutebi: transforming breast cancer care in Africa.
Lancet. 2024;403:1975. PubMed
COLES CE, Haviland JS, Kirby AM, Griffin C, et al Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors'
reply.
Lancet. 2024;403:1752. PubMed
GREGUCCI F, Ciabattoni A Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1751-1752. PubMed
MULLIEZ T, De Ridder M Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1751. PubMed
GUINOT JL, Gutierrez C, Hannoun-Levi JM Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1750-1751. PubMed
MIZUMOTO M, Oshiro Y, Sakurai H Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1749-1750. PubMed
ZHAO D, Li Y, Qu Y, He C, et al Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Lancet. 2024;403:1749. PubMed
April 2024
DE SOUZA IC, Langer FW Post-radiation angiosarcoma of the breast in a patient with a history of invasive
ductal carcinoma.
Lancet. 2024;403:1681-1682. PubMed
MOODLEY J, Unger-Saldana K The role of racial and ethnic discrimination in breast cancer disparities.
Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699. PubMed
COLES CE, Earl H, Anderson BO, Barrios CH, et al The Lancet Breast Cancer Commission.
Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747. PubMed
SAMARASEKERA U Charlotte Coles: collaborating to tackle breast cancer inequities.
Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752. PubMed
EARL HM Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535. PubMed
PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al 3-year invasive disease-free survival with chemotherapy de-escalation using an
(18)F-FDG-PET-based, pathological complete response-adapted strategy in
HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2
trial.
Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054. PubMedAbstract available
March 2024
BRAYBROOKE J, Bradley R, Gray R, Hills R, et al Benefits and risks of anthracyclines in early-stage breast cancer - Authors'
reply.
Lancet. 2024;403:1240. PubMed
KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D Benefits and risks of anthracyclines in early-stage breast cancer.
Lancet. 2024;403:1239-1240. PubMed
HICKEY M, Basu P, Sassarini J, Stegmann ME, et al Managing menopause after cancer.
Lancet. 2024;403:984-996. PubMedAbstract available